4 Big Drug Stocks That May Continue to Outperform in 2025
Portfolio Pulse from
Gilead, Eli Lilly, Vertex Pharmaceuticals, and AbbVie have outperformed the drug industry this year and are expected to maintain their momentum into 2025.
December 17, 2024 | 4:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie has outperformed the drug industry this year and is expected to continue its momentum into 2025.
AbbVie's strong performance relative to the industry suggests continued investor confidence and potential for further stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Gilead has outperformed the drug industry this year and is expected to continue its momentum into 2025.
Gilead's strong performance relative to the industry suggests continued investor confidence and potential for further stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Eli Lilly has outperformed the drug industry this year and is expected to continue its momentum into 2025.
Eli Lilly's strong performance relative to the industry suggests continued investor confidence and potential for further stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Vertex Pharmaceuticals has outperformed the drug industry this year and is expected to continue its momentum into 2025.
Vertex Pharmaceuticals' strong performance relative to the industry suggests continued investor confidence and potential for further stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100